Berlin (Germany) and Germantown, MD (U.S.A.), April 18, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, will present data from a validation study with a proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer at the Annual Meeting 2016 of the American Association for Cancer Research (AACR) in New Orleans, Louisiana.
Epigenomics´ clinical research has received funding under the European Union Framework Program for Research and Innovation (Horizon 2020*) and is part of the ongoing development of the company’s novel, blood-based lung cancer test Epi proLung®. Liquid biopsy tests such as Epigenomics’ Epi proColon® and Epi proLung® tests have the potential to radically improve cancer diagnosis in the relevant patient populations.
The poster titled “Classification of patients with lung cancer and benign lung disease via assessment of DNA methylation of SHOX2 and PTGER4 in plasma” will be presented by Dr. Gunter Weiss, Epigenomics’ Vice President Product Development, today, Monday, April 18, 2016, in a poster session.
Presentation details
Abstract No: 2260
Title: Biomarkers for Lung Cancer
Authors: A. Schlegel, O. Hasinger, S. Esche, M. Martini, T. König, G. Weiss
Time: Monday, April 18, 2016, 1.00 pm – 5.00 pm
Location: Convention Center, Halls G-J, Poster Section 22
Session Category: Clinical Research
About lung cancer
According to the World Health Organization, lung cancer is the leading cause of cancer death worldwide. The vast majority of cases of lung cancer are due to long-term exposure to tobacco smoke. Early detection and treatment of lung cancer can save lives: Survival rates for patients with lung cancer fall as the stage at diagnosis becomes more advanced.
About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon®, is a blood-based screening test for the early detection of colorectal cancer. Epi proColon® has recently received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in Europe, China and selected other countries. For more information, visit www.epigenomics.com.
*This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 672680.
Epigenomics´ clinical research has received funding under the European Union Framework Program for Research and Innovation (Horizon 2020*) and is part of the ongoing development of the company’s novel, blood-based lung cancer test Epi proLung®. Liquid biopsy tests such as Epigenomics’ Epi proColon® and Epi proLung® tests have the potential to radically improve cancer diagnosis in the relevant patient populations.
The poster titled “Classification of patients with lung cancer and benign lung disease via assessment of DNA methylation of SHOX2 and PTGER4 in plasma” will be presented by Dr. Gunter Weiss, Epigenomics’ Vice President Product Development, today, Monday, April 18, 2016, in a poster session.
Presentation details
Abstract No: 2260
Title: Biomarkers for Lung Cancer
Authors: A. Schlegel, O. Hasinger, S. Esche, M. Martini, T. König, G. Weiss
Time: Monday, April 18, 2016, 1.00 pm – 5.00 pm
Location: Convention Center, Halls G-J, Poster Section 22
Session Category: Clinical Research
About lung cancer
According to the World Health Organization, lung cancer is the leading cause of cancer death worldwide. The vast majority of cases of lung cancer are due to long-term exposure to tobacco smoke. Early detection and treatment of lung cancer can save lives: Survival rates for patients with lung cancer fall as the stage at diagnosis becomes more advanced.
About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon®, is a blood-based screening test for the early detection of colorectal cancer. Epi proColon® has recently received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in Europe, China and selected other countries. For more information, visit www.epigenomics.com.
*This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 672680.
